GENERATION DEPENDENT TARGETING POTENTIAL OF DONEPEZIL LOADED POLY (PROPYLENEIMINE) DENDRIMER THROUGH GOAT NASAL MUCOSA
Objective: In the domain of nano drug delivery, dendrimers are the most explored bioactive polymeric carrier system. The present work was aimed to study the diffusion potential of different generations of Poly (propyleneimine) (PPI) dendrimers on goat nasal mucosa in an ex vivo study and synthesize a stable dendrimer for olfactory drug delivery.
Methods: The generations (3.0G, 4.0G, and 5.0G) of PPI dendrimer were synthesized, and PEGylated by MPEG 5000 and then loaded with donepezil. A comparative study was carried out among all generations in term of their drug loading capacity, stability, sustained release behaviour as well as for targeting efficacy. An ex-vivo study was carried out on Franz Diffusion Cell with goat nasal mucosa.
Results: The developed G3, G4, and G5 dendrimerformulations had entrapment efficiency of 24.33Â±0.56%, 40.12Â±0.62%, and 60.4Â±0.6%, respectively. The nasal diffusion study revealed that 5.0G PPI dendrimer increased diffusion of donepezil up to 47% as compared to the pure solution of donepezil while 10% improvement in diffusion was seen as compared to 4.0 G PPI dendrimer. Thus obtained results claimed that the drug loading as well as targeting potential of PPI dendrimers increased with the increase in the number of generation. The investigation outcome indicated promising results of 5.0G PPI dendrimer over the 3.0G and 4.0G PPI dendrimer generations for their drug loading capacity, stability, and sustained release action.
Conclusion: The 5.0G PPI dendrimer proved its superior candidature over the other lower generations of PPI dendrimers for drug delivery and drug targeting.
2. Akhter S, Ahmad I, Ahmad MZ, Ramazani F, Singh A, Rahman Z, et al. Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets 2013;13:362-78.
3. Mody N, Tekade RK, Mehra NK, Chomedey P, Jain NK. Dendrimer, liposomes, carbon nanotubes, and PLGA nanoparticles: one platform assessment of drug delivery potential. AAPS PharmSciTech 2014;15:388–99.
4. Jain A, Kesharwani P, Garg NK, Nirbhavane P, Dwivedi N, Banerjee S, et al. Nano-constructed carriers loaded with antioxidant: boon for the cardiovascular system. Curr Pharm Des 2015;21:4456–64.
5. Bonde S, Nair S. Advances in liposomal drug delivery system: fascinating types and potential applications. Int J Appl Pharma 2017;3:1-7.
6. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2009;109:49-87.
7. Dwivedi N, Shah J, Mishra V, Mohd Amin MCI, Iyer AK, Tekade RK, et al. Dendrimer-mediated approaches for the treatment of brain tumor. J Biomater Sci 2016;5063:1–24.
8. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014;39:268-307.
9. M. Naito, T Yokoyama, K Hosokawa, K Nogi. Nanoparticle technology handbook. Elsevier; 2018.
10. Gorain B, Choudhury H, Pandey M, Amin MCIM, Singh B, Gupta U, et al. Dendrimers as effective carriers for the treatment of brain tumor, in the nanotechnology-based target. Drug Delivery Syst Brain 2018:267–305. DOI: 10.1016/B978-0-12-812218-1.00010-5
11. Anitha P, Bhargavi J, Aruna B, Ramkanth S. Recent progress of dendrimer in drug delivery for cancer therapy. Int J Appl Pharma 2018;10:34-42.
12. Mishra V, Gupta U, Jain NK. Influence of different generations of poly(propyleneimine) dendrimers on human erythrocytes. Pharmazie 2010;65:891-5.
13. Thakur S, Tekade RK, Kesharwani P, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers. J Nanoparticle Res 2013;15:162.
14. De Brabander van den Berg E, Meijer EW. Poly (propylene imine) dendrimers: large-scale synthesis by heterogeneously catalyzed hydrogenations. Angew Chem Int 1993;32:1308–11.
15. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH-responsive simultaneous drug-release kinetics. J Microencapsul 2009;26:287–96.
16. Kesharwani P, Gajbhiye V, K Tekade R, K Jain N. Evaluation of dendrimer safety and efficacy through cell line studies. Curr Drug Targets 2011;12:1478–97.
17. Hashemi M, Ayatollahi S, Parhiz H, Mokhtarzadeh A, Javidi S, Ramezani M. PEGylation of polypropylenimine dendrimer with alkylcarboxylate chain linkage to improve DNA delivery and cytotoxicity. Appl Biochem Biotechnol 2015;177:1–17.
18. Bhadra D, Bhadra S, Jain S, Jain NK, A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003;257:111–24.
19. Asmari A, Press D. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Design Development Ther 2016;10:205–15.
20. Thakur S, Kesharwani P, Tekade RK. Impact of PEGylation on biopharmaceutical properties of dendrimers. Polymer 2015;59:67–92.
21. Yeh TH, Hsu LW, Tseng MT, Lee PL, Sonja K, Ho YC, et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011;32:6164–73.
22. Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Controlled Release 2014;190:189–200.
23. Washington N, Steele RJC, Jackson SJ, Bush D, Mason J, Gill DA, et al. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm 2000;198:139–46.